|
|
(1) Leukotriene antagonists in paediatric asthma
The role of leukotriene antagonists, especially in paediatrics,
remains unclear. This article, part of an occasional feature
of drugs reviews, examines the evidence
(PDF
55K)
Hospital Pharmacist, September 2004, 341-342. Vol 11, no
8
|
|
(2) Novel drug for relapsed or chemo-resistant myeloma
Bortezomib, a proteasome inhibitor, is a new treatment option recently granted
a UK licence. This article, part of an occasional feature of drugs reviews,
examines the evidence
(PDF 60K)
Hospital Pharmacist, October 2004, 394-396. Vol 11, no 9
|
|
(3) Transdermal oxybutynin in overactive bladder
Although yet to gain a UK licence, transdermal oxybutynin, which is claimed to reduce the incidence of anticholinergic side effects, is being requested by many prescribers. This article, part of an occasional feature of new drug reviews, examines the clinical evidence
(PDF 60K)
Hospital Pharmacist, December 2004, 467-468. Vol 11, no 11
|
|
(4) Ibuprofen for treating patent ductus arteriosus in neonates
The availability of a licensed formulation of intravenous ibuprofen has resulted
in it being considered for treating patent ductus arteriosus in neonates. This
article, part of an occasional feature of drug reviews, examines the clinical
evidence
(PDF 70K)
Hospital Pharmacist, July/August 2005, 273-274. Vol 12, no 7
|
| |
|
| • Most
photographs have been removed from the PDF files for copyright reasons.
• The contents of the Pharmaceutical
Journal, associated publications and all PDF files are the property
of the Royal Pharmaceutical Society. See Copyright
for our rights. |
| Photocopies
Photocopies of articles can be ordered from the Society’s library
(library@rpsgb.org.uk);
for details click here |
| Reprints
Details on multiple reprints of the original articles are here |
|
